Text Size

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis

Hamacher T., Airaksinen J., Saarela V., Liinamaa M.J., Richter U., Ropo A.


  • 2008
  • Acta Ophthalmologica
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Augenzentrum Dr Hamacher Praxis, Maximilianstrasse 2B D-82319, Starnberg, Germany; Department of Ophthalmology, Oulu University Hospital, Oulu, Finland; Private Practice, Regensburg, Germany; Department of Clinical Research, Santen Oy, Helsinki, Finland

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group


Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.


Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022